Surmodics (SRDX) Competitors $29.04 -0.24 (-0.80%) Closing price 03:59 PM EasternExtended Trading$28.98 -0.06 (-0.21%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRDX vs. ATEC, ATRC, IART, OFIX, ANGO, ARAY, RMTI, RSLS, ABT, and ISRGShould you be buying Surmodics stock or one of its competitors? The main competitors of Surmodics include Alphatec (ATEC), AtriCure (ATRC), Integra LifeSciences (IART), Orthofix Medical (OFIX), AngioDynamics (ANGO), Accuray (ARAY), Rockwell Medical (RMTI), ReShape Lifesciences (RSLS), Abbott Laboratories (ABT), and Intuitive Surgical (ISRG). These companies are all part of the "health care equipment" industry. Surmodics vs. Its Competitors Alphatec AtriCure Integra LifeSciences Orthofix Medical AngioDynamics Accuray Rockwell Medical ReShape Lifesciences Abbott Laboratories Intuitive Surgical Surmodics (NASDAQ:SRDX) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations. Does the media refer more to SRDX or ATEC? In the previous week, Alphatec had 2 more articles in the media than Surmodics. MarketBeat recorded 5 mentions for Alphatec and 3 mentions for Surmodics. Alphatec's average media sentiment score of 0.92 beat Surmodics' score of 0.79 indicating that Alphatec is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surmodics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alphatec 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, SRDX or ATEC? Surmodics has higher earnings, but lower revenue than Alphatec. Surmodics is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSurmodics$126.08M3.29-$11.54M-$1.39-20.89Alphatec$611.56M2.60-$162.12M-$1.15-9.47 Do analysts recommend SRDX or ATEC? Surmodics currently has a consensus target price of $43.00, suggesting a potential upside of 48.10%. Alphatec has a consensus target price of $17.89, suggesting a potential upside of 64.34%. Given Alphatec's stronger consensus rating and higher probable upside, analysts clearly believe Alphatec is more favorable than Surmodics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Surmodics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Alphatec 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Do insiders and institutionals have more ownership in SRDX or ATEC? 96.6% of Surmodics shares are held by institutional investors. Comparatively, 66.4% of Alphatec shares are held by institutional investors. 8.9% of Surmodics shares are held by company insiders. Comparatively, 22.8% of Alphatec shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is SRDX or ATEC more profitable? Surmodics has a net margin of -16.34% compared to Alphatec's net margin of -25.77%. Surmodics' return on equity of -7.10% beat Alphatec's return on equity.Company Net Margins Return on Equity Return on Assets Surmodics-16.34% -7.10% -4.77% Alphatec -25.77%-1,657.19%-21.53% Which has more volatility & risk, SRDX or ATEC? Surmodics has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. SummaryAlphatec beats Surmodics on 9 of the 16 factors compared between the two stocks. Get Surmodics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRDX vs. The Competition Export to ExcelMetricSurmodicsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$414.91M$10.34B$5.50B$8.93BDividend YieldN/A2.11%5.38%4.12%P/E Ratio-20.8716.9326.2519.86Price / Sales3.2927.25415.14113.78Price / Cash96.0322.8736.4957.06Price / Book3.493.648.055.38Net Income-$11.54M$233.36M$3.16B$248.50M7 Day Performance0.43%1.31%1.78%2.78%1 Month Performance-1.48%3.15%4.74%5.84%1 Year Performance-30.82%-11.83%35.81%20.06% Surmodics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRDXSurmodics4.5325 of 5 stars$29.04-0.8%$43.00+48.1%-30.1%$414.91M$126.08M-20.87450News CoverageAnalyst RevisionATECAlphatec4.2316 of 5 stars$11.10+0.2%$17.89+61.2%+9.5%$1.62B$611.56M-9.65700ATRCAtriCure3.5399 of 5 stars$32.77+1.5%$50.67+54.6%+43.1%$1.60B$465.31M-40.461,300Positive NewsIARTIntegra LifeSciences4.091 of 5 stars$12.27-0.2%$18.63+51.8%-54.3%$955.08M$1.61B-32.294,396OFIXOrthofix Medical3.0613 of 5 stars$11.15+0.5%$21.50+92.8%-13.2%$434.52M$799.49M-3.021,616Gap UpANGOAngioDynamics3.9752 of 5 stars$9.92+1.4%$14.00+41.1%+66.4%$397.14M$303.91M-9.82760Positive NewsARAYAccuray3.6287 of 5 stars$1.37-0.7%N/A-22.7%$142.16M$446.55M-27.401,040Positive NewsRMTIRockwell Medical4.205 of 5 stars$0.85+7.1%$4.00+371.7%-50.2%$27.07M$101.49M-42.40300News CoverageGap DownRSLSReShape Lifesciences0.1556 of 5 stars$2.44flatN/A-99.2%$5.82M$8.01M-0.0150ABTAbbott Laboratories4.8923 of 5 stars$136.09+1.3%$142.61+4.8%+32.0%$233.80B$41.95B17.65114,000Positive NewsISRGIntuitive Surgical4.3172 of 5 stars$543.41+1.8%$588.95+8.4%+23.3%$191.29B$8.35B79.6815,638Positive News Related Companies and Tools Related Companies Alphatec Competitors AtriCure Competitors Integra LifeSciences Competitors Orthofix Medical Competitors AngioDynamics Competitors Accuray Competitors Rockwell Medical Competitors ReShape Lifesciences Competitors Abbott Laboratories Competitors Intuitive Surgical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRDX) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surmodics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surmodics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
